AzTrials
AzTrials

Myocardial Infarction, AcuteWAMIF-suiviNCT07181317

WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction: Cohort Follow up

An observational study of Myocardial Infarction, Acute, run by French Cardiology Society at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their… Read more about this study

Who is it for?
Ages 18 to 60 years, women only
Conditions the study is for
Myocardial Infarction, Acute
What is being tested?
Questionnaires and Major events
How many people
314 participants
Where
1 siteFrance
Study dates
25 Nov 2025to 30 Sep 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: 314 women who had a myocardial infarction at less than 50 years, included in the WAMIF study conducted from 2017 to 2019 in 30 French research centers.

All patients who participated in the WAMIF study (research registration number with the French Ministry of Health : 2015-A01263-46 / Protocol registration with Clinical Trials NCT03073447) and wish to continue follow-up in the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tessa BERGOT, MSc contact

+33144907033

tessa.bergot@sfcardio.fr

France1 site, 1 recruiting

  • Hôpital de la Pitié Salpétrière

    Paris, 75012

    Stéphane MANZO-SILBERMANN, MD

    Recruiting

Other trials in France

About this study

Official title: WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction in France: Clinical, Morphological and Biological Descriptive Analysis: Cohort Follow up

The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients.

Read the detailed description

The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. The main results were: a particularly high incidence of modifiable risk factors affecting 86% of patients, with smoking being the primary cause in 75% of them.The clinical presentation found chest pain in more than 90% of cases. The pathophysiological forms of acute coronary syndrome identified the culprit artery in 90% of cases, a form without obstruction (MINOCA) was found in 17.8% of ST segment elevation infarctions (STEMI), spontaneous dissection in 14.6% of STEMI and 16.3% of NSTEMI.At 12 months, follow-up showed no cardiovascular deaths and two deaths related to neoplastic causes. At the end of this follow-up, 90% had no events. Compared to existing studies, these event rates are extremely low. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients. The secondary objective is the evaluation of the quality of life and mental health of women who have had an MI before the age of 50 years at a distance from the acute event.

Being tested
Questionnaires, Major events
Medical subject headings
Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • QuestionnairesOther

    Assessment of stress and anxiety and quality of life after myocardial infarct:

    • Stress score: Perceived Stress Scale-4 (PSS-4)
    • Anxiety score: Generalized Anxiety Disorder-7 (GAD-7)
    • Depression score: Patient Health Questionnaire-9 (PHQ-9)
    • Quality of life scores: European Quality of Life-5 Dimensions (EQ-5D) and 12-Item Short-Form General Health Survey (SF-12)

  • Major eventsOther

    Collection of information related to major events occurring since inclusion in the WAMIF study

Study groups in NCT07181317
Study groupRoleWhat they receive
WAMIF patientsAll patients who participated in the WAMIF study (NCT 03073447) and wish to continue follow-up in the present "WAMIF-suivi" study.
Receives: Other: Questionnaires; Other: Major events

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Death from any cause

    Number of patient who died from any cause since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  2. Cardiovascular death

    Number of patient who died from cardiovascular cause since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  3. Stent thrombosis

    Number of patient who had stent thrombosis since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  4. Stroke

    Number of patient who had stroke since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  5. Recurrent myocardial infarct

    Number of patient who had recurrent myocardial infarct since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  6. Emergency revascularization

    Number of patient who had emergency revascularization since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  7. Major bleeding

    Number of patient who had since major bleeding their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  8. Emergency hospitalization for heart failure

    Number of patient who had emergency hospitalization for heart failure since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

  9. Emergency department visit

    Number of patient who went to emergency department since their participation in WAMIF study

    Measured: 5 to 10 years after the participation in WAMIF study

Secondary outcomes (5)

  1. Stress score

    Perceived Stress Scale 4 items. It provides a total score (range 10-50, from worst to best) to assess the state of stress perceived by the patient

    Measured: 5 to 10 years after the participation in WAMIF study

  2. Anxiety score

    Generalized Anxiety Disorder 7 items. It provides a total score to evaluate patient anxiety (range 0 to 21: 0-4: minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; 15-21: severe anxiety)

    Measured: 5 to 10 years after the participation in WAMIF study

  3. Depression score

    Patient Health Questionnaire 9 items. It provides a total score (range 0-27, 1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; 20-27 severe depression) to diagnose and measure severity of depression.

    Measured: 5 to 10 years after the participation in WAMIF study

  4. Quality of life score

    European Quality of Life 5 Dimensions. It provides a total score (range 0-100, from worst to the best) to evaluate the generic quality of life

    Measured: 5 to 10 years after the participation in WAMIF study

  5. Quality of life score

    12 Item Short Form General Health Survey. It determines a respondent's profile in eight fields: physical function, physical role, physical pain, general health, vitality, social functioning, emotional role, and mental health

    Measured: 5 to 10 years after the participation in WAMIF study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2025
  2. Study start25 Nov 2025
  3. Primary completion30 Sep 2029 (estimated)
  4. Study completion30 Sep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
314 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07181317
Sponsor's protocol ID
2025-04
Acronym
WAMIF-suivi
Status last verified
Jan 2026
First submitted
8 Sep 2025
Last updated
12 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Infarction, Acute, run by French Cardiology Society at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tessa BERGOT, MSc (+33144907033, tessa.bergot@sfcardio.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Death from any cause (time frame: 5 to 10 years after the participation in WAMIF study). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07181317.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026; AzTrials last refreshed its copy on 7 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in